Loading…
aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C
Aims Hepatocellular carcinoma (HCC) can still occur in hepatitis C virus (HCV) patients who have achieved a sustained virologic response (SVR), which remains an important clinical issue in the direct‐acting antivirals era. The current study investigated the clinical utility of the aMAP score (consis...
Saved in:
Published in: | Hepatology research 2021-09, Vol.51 (9), p.933-942 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Aims
Hepatocellular carcinoma (HCC) can still occur in hepatitis C virus (HCV) patients who have achieved a sustained virologic response (SVR), which remains an important clinical issue in the direct‐acting antivirals era. The current study investigated the clinical utility of the aMAP score (consisting of age, male, albumin–bilirubin, and platelets) for predicting HCC occurrence in HCV patients achieving an SVR by direct‐acting antivirals.
Methods
A total of 1113 HCV patients without HCC history, all of whom achieved an SVR, were enrolled for clinical comparisons.
Results
Hepatocellular carcinoma was recorded in 50 patients during a median follow‐up period of 3.7 years. The aMAP score was significantly higher in the HCC occurrence group than in the HCC‐free group (53 vs. 47, p |
---|---|
ISSN: | 1386-6346 1872-034X |
DOI: | 10.1111/hepr.13689 |